Citadel Advisors’s ESSA Pharma EPIX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q4 | – | Sell |
-22,100
| Closed | -$4.22K | – | 12992 |
|
|
2025
Q3 | $4.22K | Sell |
22,100
-40,900
| -65% | -$49K | ﹤0.01% | 12579 |
|
|
2025
Q2 | $107K | Buy |
63,000
+62,800
| +31,400% | +$106K | ﹤0.01% | 11282 |
|
|
2025
Q1 | $316 | Sell |
200
-14,900
| -99% | -$25.2K | ﹤0.01% | 14285 |
|
|
2024
Q4 | $27K | Sell |
15,100
-5,900
| -28% | -$18.8K | ﹤0.01% | 12966 |
|
|
2024
Q3 | $127K | Buy |
21,000
+17,200
| +453% | +$94.5K | ﹤0.01% | 10793 |
|
|
2024
Q2 | $20K | Sell |
3,800
-9,900
| -72% | -$62.9K | ﹤0.01% | 12641 |
|
|
2024
Q1 | $116K | Buy |
13,700
+12,200
| +813% | +$107K | ﹤0.01% | 11149 |
|
|
2023
Q4 | $9.9K | Sell |
1,500
-5,900
| -80% | -$29.1K | ﹤0.01% | 13134 |
|
|
2023
Q3 | $22.9K | Sell |
7,400
-2,000
| -21% | -$5.76K | ﹤0.01% | 12518 |
|
|
2023
Q2 | $25.4K | Sell |
9,400
-39,500
| -81% | -$116K | ﹤0.01% | 12528 |
|
|
2023
Q1 | $145K | Buy |
48,900
+7,200
| +17% | +$21.2K | ﹤0.01% | 10690 |
|
|
2022
Q4 | $105K | Buy |
+41,700
| New | +$120K | ﹤0.01% | 11141 |
|
Citadel Advisors's EPIX Position: Q4 2025 in Review
Citadel Advisors sold out of ESSA Pharma (EPIX) in Q4 2025, closing a stake of 144,449 shares — an estimated $27.6K sold.
Citadel Advisors first reported a position in EPIX in Q2 2017 and held it in 20 quarters. The position peaked at $20.6M in Q2 2021. 0 funds tracked by Wall St. Rank hold EPIX as of Q4 2025.
- Citadel Advisors reported no remaining ESSA Pharma position as of Q4 2025 after selling out during the quarter.
- Citadel Advisors sold 144,449 ESSA Pharma shares in Q4 2025, an estimated $27.6K.
- Citadel Advisors first reported a position in ESSA Pharma in Q2 2017 and held it in 20 quarters.
- Citadel Advisors's ESSA Pharma position peaked at $20.6M in Q2 2021.
- 0 funds tracked by Wall St. Rank held ESSA Pharma as of Q4 2025.
Based on Citadel Advisors's 13F filing for Q4 2025, filed 17 Feb 2026.